Background: Noroviruses are the most common cause of viral gastroenteritis worldwide, yet there is a deficit in the understanding of protective immunity. Surrogate neutralization assays have been widely used that measure the ability of antibodies to block virus-like particle (VLP) binding to histo-blood group antigens (HBGAs). However, screening large sample sets against multiple antigens using the traditional HBGA blocking assay requires significant investment in terms of time, equipment, and technical expertise, largely associated with the generation of purified VLPs.
Methods: To address these issues, a luciferase immunoprecipitation system (LIPS) assay was modified to measure the norovirus-specific HBGA blockade activity of antibodies. The assay (designated LIPS-Blockade) was validated using a panel of well-characterized homotypic and heterotypic hyperimmune sera as well as strain-specific HBGA blocking monoclonal antibodies.
Results: The LIPS-Blockade assay was comparable in specificity to a standard HBGA blocking protocol performed with VLPs. Using time-ordered patient sera, the luciferase-based approach was also able to detect changes in HBGA blocking titers following viral challenge and natural infection with norovirus.
Conclusion: In this study we developed a rapid, robust, and scalable surrogate neutralization assay for noroviruses that circumvented the need for purified VLPs. This LIPS-Blockade assay should streamline the process of large-scale immunological studies, ultimately aiding in the characterization of protective immunity to human noroviruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924141 | PMC |
| http://dx.doi.org/10.1016/j.jviromet.2021.114196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Precursor of H-Type II Histo-Blood Group Antigen and Subterminal Sialic Acids on Gangliosides Are Significantly Implicated in Cell Entry and Infection by a Porcine P[11] Rotavirus.
Emerg Microbes Infect
December 2024
Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany.
Rotaviruses, non-enveloped viruses with a double-stranded RNA genome, are the leading etiological pathogen of acute gastroenteritis in young children and animals. The P[11] genotype of rotaviruses exhibits a tropism for neonates. In the present study, a binding assay using synthetic oligosaccharides demonstrated that the VP8* protein of P[11] porcine rotavirus (PRV) strain 4555 binds to lacto-N-neotetraose (LNnT) with the sequence Galβ1,4-GlcNAcβ1,3-Galβ1,4-Glc, one of the core parts of histo-blood group antigen (HBGA) and milk glycans.
View Article and Find Full Text PDFBiological and immunological characterization of major capsid protein VP1 from distinct GII.2 norovirus clusters.
Sci Rep
September 2024
Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Center for Translational Medicine, Zhengzhou, 450000, People's Republic of China.
Human noroviruses (HuNoVs) are a leading cause of acute viral gastroenteritis worldwide. Infectious outbreaks due to recombinant NoV genotype called GII.P16-GII.
View Article and Find Full Text PDFDevelopment of a broad-spectrum therapeutic Fc-nanobody for human noroviruses.
J Virol
July 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Article Synopsis
- Human norovirus, a major cause of acute gastroenteritis outbreaks, lacks approved vaccines or antivirals, but recent research on norovirus inhibitors like monoclonal antibodies (Mabs) and nanobodies shows promise in blocking virus replication.
- The study focused on enhancing a cross-reactive nanobody (NB26) by conjugating it with a human IgG Fc domain to create Fc-NB26, which displayed significantly improved binding and neutralization capabilities against various norovirus strains.
- The findings indicate that structural modifications to nanobodies not only heighten their efficacy but also offer potential pathways for developing broad-spectrum therapeutics against the evolving norovirus landscape.
Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels.
J Infect Dis
December 2024
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Background: The in vitro cultivation of human noroviruses allows a comparison of antibody levels measured in neutralization and histo-blood group antigen (HBGA)-blocking assays.
Methods: Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed for neutralizing antibody levels against the vaccine's prototype Norwalk virus/genogroup I, genotype 1 (GI.1) (P1) virus strain.
GII.6 norovirus major capsid protein VP1 derived from distinct clusters induce cross-blocking effects.
Infect Genet Evol
August 2024
Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Center for Translational Medicine, Zhengzhou 450000, People's Republic of China. Electronic address:
Article Synopsis
- GII.6 norovirus shows less variation in its major capsid protein VP1 compared to GII.4, which the study investigates across three distinct GII.6 strains.
- The team expressed VP1 using a recombinant system and analyzed it through various methods, including mass spectrometry, to characterize its molecular properties and binding abilities.
- Results indicated similar binding capabilities among the different GII.6 strains with observed cross-blocking effects, implying fewer strains may be necessary for effective vaccine development against norovirus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!